Table 1.
Baseline demographics of the patients enrolled onto the study
| Characteristics | n | |
|---|---|---|
| Age, yrs | 168 | 69.8 (8.1) |
| Gender, (% Male) | 168 | 74 |
| Current Smoker, (%) | 168 | 32 |
| Inhaled steroid use (%) | 168 | 86 |
| Inhaled steroid dose (μg) (BDP equivalent) | 168 | 1000 [200–2000] |
| LABA use (%) | 168 | 88 |
| LAMA use (%) | 168 | 78 |
| Pack Years | 168 | 47.0 [10.0–220.0] |
| BMI (kg/m2) | 168 | 26.2 [18.0–45.0] |
| FFMI (kg/m2) | 159 | 17.8 (3.5) |
| Chronic Bronchitis (%) | 164 | 73 |
| Exacerbation rate (prior study entry) | 168 | 1.0 [0.0–15.0] |
| SGRQ total | 162 | 47.8 (18.4) |
| mMRC score | 145 | 2.0 [1.0–4.0] |
| CAT score | 165 | 18.7 (7.1) |
| 6MWD | 132 | 380.9 (109.4) |
| KCO, % | 119 | 75.4 (27.0) |
| Pre FEV1 (L) | 104 | 1.5 (0.6 |
| Pre FEV1% | 104 | 55.7 (19.9) |
| Pre FVC (L) | 104 | 3.0 (0.9) |
| Pre FEV1/FVC | 104 | 0.5 (0.1) |
| Post FEV1 (L) | 168 | 1.5 (0.6) |
| Post FEV1% | 168 | 56.8 (18.9) |
| Post FVC (L) | 168 | 3.0 (0.9) |
| Post FEV1/FVC | 168 | 0.5 (0.1) |
| Reversibility % | 105 | 7.2 [−13.0–32.5] |
| Reversibility ml | 105 | 100 [−180–420] |
| Sputum Total Cell Count x106/g | 90 | 3.7 [0.2–84.6] |
| Sputum Neutrophil % | 94 | 76.0 [1.0–99.3] |
| Sputum Eosinophil % | 94 | 0.8 [0.0–13.2] |
| Sputum Neutrophil cell count x106/g | 90 | 2.5 [0.0–82.4] |
| Sputum Eosinophil cell count x106/g | 90 | 0.03 [0.0–0.5] |
| PPM positive (≥1 × 104 copies/ml), % | 168 | 52 |
Summaries are presented as mean (SD), median [Range] and percentages as appropriate
Definitions of abbreviations: BDP Beclometasone dipropionate equivalent, LABA Long Acting Beta Agonist, LAMA Long Acting muscarinic antagonist, BMI Body Mass Index, FFMI, Fat Free Mass Index; SGRQ St George’s Respiratory Questionnaire, mMRC modified Medical Research Council, CAT COPD Assessment Test, 6MWD 6 min walk test, FEV 1 Forced Expired Volume in first second, FVC Forced vital capacity, PPM Potentially pathogenic microorganism, Pre Pre bronchodilator, Post Post bronchodilator